Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium Ga 68 dotatate + fludeoxyglucose F 18
- Development stage
- Unknown
- Lead developer
- Advanced Accelerator Applications
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
68Ga + NETSPOT + 18F-FDG refers to the combined use of two diagnostic radiopharmaceutical imaging agents, gallium Ga 68 dotatate (NETSPOT) and fludeoxyglucose F 18 (18F-FDG), in clinical imaging protocols. Gallium Ga 68 dotatate is a radiolabeled somatostatin analog that binds with high affinity to somatostatin receptors (SSTRs), particularly SSTR2, which are frequently overexpressed in neuroendocrine tumors and certain squamous cell carcinomas. Fludeoxyglucose F 18 is a glucose analog that is taken up by cells via glucose transporters (GLUT) and phosphorylated by hexokinase; its accumulation reflects the rate of glucose consumption, which is typically elevated in malignant cells. This combination is being investigated in Phase 2 clinical trials (e.g., NCT03602911) to compare the diagnostic performance of SSTR-targeted PET/CT against standard FDG-PET/CT in patients with head and neck squamous cell carcinoma (HNSCC), aiming to improve tumor localization and post-treatment surveillance.
- Other names
- 68Ga-DOTATATE + 18F-FDGNETSPOT + FDGNETSPOT + 18F-FDG
02
Targets
SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)GCK (Glucokinase)SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on gallium Ga 68 dotatate + fludeoxyglucose F 18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium Ga 68 dotatate + fludeoxyglucose F 18.